Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis

The Journal of Antimicrobial Chemotherapy
Hekun MeiYun Cai

Abstract

Use of tigecycline in treating MDR Acinetobacter baumannii (MDRAB) remains controversial. To comprehensively assess the safety and efficacy of tigecycline in pneumonia caused by Acinetobacter baumannii. PubMed, Embase, Web of Science and Cochrane library databases were searched up to 12 March 2019. Studies were included if they compared tigecycline-based regimens with other antibiotic regimens for treating AB pulmonary infections and we pooled the clinical outcomes, microbiological response, adverse events or mortality. One prospective study and nine retrospective studies were included in this meta-analysis. The results showed similar clinical cure rates (OR = 1.04, 95% CI = 0.60-1.81; P = 0.89) and mortality rates (OR = 1.11, 95% CI = 0.65-1.89; P = 0.71) comparing tigecycline groups with the control groups. However, a significantly lower microbiological eradication rate was found in the tigecycline groups (OR = 0.43, 95% CI = 0.27-0.66; P = 0.0001). Incidence of nephrotoxicity in tigecycline-based regimens was significantly lower than in colistin-based regimens (OR = 0.34, 95% CI = 0.16-0.74, I2 = 35%, P = 0.006). There were no randomized controlled trials (RCTs) included; incomplete safety data and regional bias caused by th...Continue Reading

References

Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Apr 21, 2005·BMC Medical Research Methodology·Stela Pudar HozoIztok Hozo
Oct 22, 2005·Nature Reviews. Drug Discovery·Richard WenzelPeter Kirkpatrick
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·Johannes BreedtUNKNOWN Tigecycline 305 cSSSI Study Group
Jun 23, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Nishaminy Kasbekar
Jun 21, 2011·The Journal of Antimicrobial Chemotherapy·Dafna YahavLeonard Leibovici
Jul 26, 2011·The Lancet Infectious Diseases·Efthimia TasinaMalamatenia Arvanitidou
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Jul 11, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Soo-Youn MoonJae-Hoon Song
Nov 7, 2012·International Journal of Antimicrobial Agents·Yan SunRui Wang
Sep 14, 2013·Diagnostic Microbiology and Infectious Disease·Allen T GriffinDiana M Christensen
Apr 27, 2012·Infectious Disease Reports·Trupti PatelIndran Balakrishnan
Mar 8, 2014·International Journal of Antimicrobial Agents·Matthew E FalagasGiannoula S Tansarli
Mar 13, 2014·International Journal of Antimicrobial Agents·Thana KhawcharoenpornAnucha Apisarnthanarak
Jun 3, 2014·Critical Care : the Official Journal of the Critical Care Forum·Gennaro De PascaleMassimo Antonelli
Dec 31, 2014·Antimicrobial Agents and Chemotherapy·Qian ZhangJing Zhou
Aug 19, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael T Hemphill, Kellie R Jones
Nov 8, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C-A LiangC-C Sheu
Feb 25, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sajjad AhmadSyed Sikander Azam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.